DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0184742 A1 Uhr Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0184742 A1 Uhr Et Al US 20100184742A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184742 A1 Uhr et al. (43) Pub. Date: Jul. 22, 2010 (54) POLYMORPHISMS IN ABCB1 ASSOCIATED Related U.S. Application Data WITH A LACK OF CLINICAL RESPONSE TO (60) Provisional application No. 60/943,335, filed on Jun. MEDCAMENTS 12, 2007. Publication Classification (76) Inventors: Manfred Uhr, Stockdorf (DE): Florian Holsboer, Munchen (DE); (51) Int. Cl. Bertram Miller-Myhsok, A6II 3/55 (2006.01) Munchen (DE) CI2O I/68 (2006.01) C40B 20/00 (2006.01) C40B 40/06 (2006.01) Correspondence Address: A6II 3/343 (2006.01) ROTHWELL, FIGG, ERNST & MANBECK, PC. A63L/35 (2006.01) 1425 KSTREET, N.W., SUITE 800 A6IP 25/00 (2006.01) WASHINGTON, DC 20005 (US) (52) U.S. Cl. .............. 514/214.02:435/6; 506/2:506/16; 514/469; 514/653 (21) Appl. No.: 12/663,997 (57) ABSTRACT The present invention relates to methods, compositions, kits (22) PCT Filed: Jun. 12, 2008 and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the (86). PCT No.: PCT/EP2008/004.737 central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combina S371 (c)(1), tion of medicaments for the treatment of human patients (2), (4) Date: Dec. 10, 2009 having specific polymorphisms in the ABCB1 gene. Patent Application Publication Jul. 22, 2010 Sheet 1 of 4 US 2010/0184742 A1 Figure 1 Cital Opram Venlafaxine S00 500 450 abcb1ab (-f-) 450 abcb1ab (--) o controls o controls 400 400 S 350 S 350 5 300 5 300 on 250 250 200 20 O C SQ 1SO g 150 100 100 50 SO O O cer spl kid liv tes lun cer spi kid liv tes lun 500 Mirtazapine 500 D-Venlafaxine 450 abcb1ab (--) 450 abcb1ab (--) to controls to controls 400 400 S 350 S 350 5 300 5 300 s c 250 dy 250 c t- 200 t- 200 4- 5 150 150 100 50 cer spl kid liv tes lun cer spl kid liv tes lun Patent Application Publication Jul. 22, 2010 Sheet 2 of 4 US 2010/0184742 A1 Figure 2 A substrates of P-gp B Non-substrates of P-gp 00 100 80. 80 6 O 60 4. O 40 20 20 non-remitters remitters non-remitters remitters genotype rs2032583 genotype rs2032583 Patent Application Publication Jul. 22, 2010 Sheet 3 of 4 US 2010/0184742 A1 Figure 3 A All patients D All patients 100 100 Š. 80 s 80 C O 60 O 60 p l gE 40 gE 40 5 20 5 20 C-carriers (N-91) T-carriers (N=125) O - - - non-carriers (N-344) O - - - non-carriers (N-286) O 1 2 3 4 5 6 O 1 2 3 4. 5 6 time weeks time weeks B Substrates of P-glycoprotein E Substrates of P-glycoprotein 100 100 g 80 s 8O - 5 60 9 60 E 40 E 40 se s 5 20 a 20 C C-carriers (N-23) T-carriers (N-36) --- non-carriers (N=110) --- non-carriers (N=96) O 1 2 3 4. 5 6 O 1 2 3 4. s 6 time weeks time weeks C Non-substrates of P-glycoprotein F Non-substrates of P-glycoprotein 100 100 se 80 is 80 C 9 60 9 60 3. 8 E 40 E 40 g 5 20 5 20 C C-carriers (N-26) C T-carriers (N-34) --- non-carriers (N=72) --- non-carriers (N-62) O 1 2 3 4 5 6 O 2 3 4 5 6 time weeks time weeks) Patent Application Publication Jul. 22, 2010 Sheet 4 of 4 US 2010/O184742 A1 Figure 4 US 2010/0184742 A1 Jul. 22, 2010 POLYMORPHISMS IN ABCB1 ASSOCATED 0007 WO 2005/108605 relates to polymorphisms in the WITH A LACK OF CLNICAL RESPONSE TO ABCB1 gene which are associated with an insufficient clini MEDCAMENTS cal response to a CNS active medicament which is a substrate of the ABCB1 protein. Seven single nucleotide polymor phisms (SNPs) in the ABCB1 gene are described, which are 0001. The present invention relates to methods, composi associated with clinical response to antidepressant drugs. tions, kits and reagents for determining the prognosis of a However, there is no evidence in this document that beside the clinical response in a human patient to a medicament which specific polymorphisms disclosed any further polymor acts in the central nervous system (CNS) and which is a phisms in the ABCB1 gene might be associated with a clinical substrate of the ABCB1 protein. Further, the invention relates response to CNS-active medicaments. to a combination of medicaments for the treatment of human 0008 Thus, there is still a need for identifying polymor patients having specific polymorphisms in the ABCB1 gene. phisms of the ABCB1 gene involved in regulating intracere 0002 Major depression constitutes one of the greatest dis bral concentrations of CNS-active medicaments. It was the ease burdens world-wide and is anticipated to be the second object of the present invention to determine new single nucle leading global disease burden by the year 2020 trailing only otide polymorphisms in the ABCB1 gene which are predic cardiovascular disease (Murray and Lopez, 1996). Antide tive for treatment course and outcome of CNS-active medi pressants are the first line treatment of major depression, but caments, which are ABCB1 transporter substrates. their overall clinical efficacy is unsatisfactory as remission, 0009. In the studies on which the present application is i.e. full resolution of depressive symptoms, occurs in only based the inventors surprisingly were able to identify several about half of the patients after a trial with an adequately dosed new polymorphisms in the ABCB1 gene, which have a clear single drug. Remission rates even decline following Succes and statistically relevant association with an insufficient clini sive treatment failures (Trivedi et al., 2006)). cal response to CNS-active medicaments. The inventors suc 0003. One of the possible reasons for poor antidepressant ceeded in identifying the SNPs rs4148740, rs10280101, response is their inadequate penetration into the central ner rs7787.082, rs4148739, rs1 1983225, rs10248420 and Vous system, which depends on the drug's ability to pass the rs 12720067 as particularly responsible for this association. blood-brain barrier (BBB). This barrier includes active trans The presence of these particular SNPs proved highly predic porters that are expressed at the luminal membrane of the tive for treatment course and outcome of CNS-active medi endothelial cells lining the small blood capillaries that form Caments. the blood-brain barrier. These molecules actively transport 0010. A first aspect of the invention relates to a method for their substrates against a concentration gradient out of the determining the prognosis of a clinical response in a human cells back into the blood circulation, thus potentially keeping patient to a central nervous system (CNS)-active medicament brain drug concentrations low. One of the best-studied trans which is a substrate of the ABCB1 protein wherein the pres porter molecules is P-glycoprotein (P-gp) (Cordon-Cardo et ence of at least one first polymorphism in the ABCB1 gene of al., 1989: Thiebaut et al., 1987). P-gp is a member of the said patient is determined, wherein said first polymorphism is highly conserved super-family of ATP-binding cassette selected from the group consisting of rS4148740. (ABC) transporter proteins (Ambudkar et al., 1999). In rs 10280101, rs7787.082, rs4148739, rs1 1983225, humans, this 170-kDa glycoprotein is encoded on chromo rS10248420 and rs12720067 and combinations thereof. some 7 by the ABCB1 gene, also known as the multidrug 0011. A further aspect of the invention relates to a diag resistance 1 (MDR1) gene (Callen et al., 1987; Chin et al., nostic composition or kit for the prognosis of a clinical 1989). P-gp acts as an active efflux pump for a wide range of response in a human patient to a CNS-active medicament compounds including a number of drugs and steroid hor which is a substrate of the ABCB1 protein, comprising at least mones (Schinkel et al., 1996: Uhr et al., 2000, 2002, 2004, one primer or probe for determining at least one first poly 2005). P-gp at the BBB thus regulates intracerebral concen morphism in the ABCB1 gene in said patient, wherein said trations and, by extension, may affect the clinical response of first polymorphism is selected from the group consisting of CNS-targeting drugs that are substrates of this transporter. rs4148740, rs1028O101, rs7787.082, rs4148739, rs1 1983225, 0004. It was speculated that inter-individual differences in rs 10248420, rs12720067 and combinations thereof. the activity of the ABCB1 gene can account in part for the 0012. A still further aspect of the invention relates to a great variation in clinical response to antidepressants in psy microarray for the prognosis of a clinical response in a human chiatric patients, even at comparable plasma levels (Uhr and patient to a CNS-active medicament which is a substrate of Grauner, 2003). A further study showed different enhance the ABCB1 protein comprising a carrier having immobilized ment of penetration of the antidepressants doxepin, Venlafax thereto at least one probe for determining at least one first ine and paroxetine in the brain of mice with an ABCB1ab polymorphism in the ABCB1 gene in said patient, wherein knockout mutation (Uhr, Grauer and Holsboer, 2003). said first polymorphism is selected from the group consisting 0005 Numerous papers describe polymorphisms in of rs4148740, rs1028O101, rs7787.082, rs4148739, ABCB1 (Kioka et al., 1989: Stein et al., 1994; Mickley et al., rs 11983225, rs10248420, rs12720067 and combinations 1998; Hoffmeyer et al., 2000; Kimetal., 2001; Ito et al., 2001; thereof.
Load more

Recommended publications
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Crowdsourcing Analysis of Off-Label Intervention Usage in Amyotrophic Lateral Sclersosis
    CROWDSOURCING ANALYSIS OF OFF-LABEL INTERVENTION USAGE IN AMYOTROPHIC LATERAL SCLERSOSIS A Thesis Presented to The Academic Faculty by Benjamin I. Mertens In Partial Fulfillment of the Requirements for the Degree B.S. in Biomedical Engineering with the Research Option in the Wallace H. Coulter School of Biomedical Engineering Georgia Institute of Technology Spring 2017 1 ACKNOWLEDGEMENTS I would like to thank my research advisor, Dr. Cassie Mitchell, first and foremost, for helping me through this long process of research, analysis, writing this thesis and the corresponding article to be submitted for peer-reviewed journal publication. There is no way I could have done this, or written it as eloquently without her. Next, I would like to acknowledge Grant Coan, Gloria Bowen, and Nathan Neuhart for all helping me on the road to writing this paper. Lastly, I would like to thank Dr. Lena Ting for her consultation as the faculty reader. 2 TABLE OF CONTENTS Page ACKNOWLEDGEMENTS 2 LIST OF TABLES 4 LIST OF FIGURES 5 LIST OF ABBREVIATIONS 6 SUMMARY 7 CHAPTERS 1 Philosophy 9 2 Crowdsourced Off-label Medications to Extend ALS Disease Duration 12 Introduction 12 Methodology 15 Results 18 Discussion 25 Tables 33 Figures 38 APPENDIX A: All Table 2 Appearance in Patients and Visits 44 APPENDIX B: All Table 3 Appearance in Patients and Visits 114 REFERENCES 129 3 LIST OF TABLES Page Table 1: Database Overview 33 Table 2: Ontology of Individual Medications 34 Table 3: Ontology of Intervention Groups 36 4 LIST OF FIGURES Page Figure 1: Relational circle
    [Show full text]
  • Disposition of T Oxic Drugs and Chemicals
    Disposition of Toxic Drugs and Chemicals in Man, Eleventh Edition Eleventh Edition in Man and Chemicals Drugs Toxic Disposition of The purpose of this work is to present in a single convenient source the current essential information on the disposition of the chemi- cals and drugs most frequently encountered in episodes of human poisoning. The data included relate to the body fluid concentrations of substances in normal or therapeutic situations, concentrations in fluids and tissues in instances of toxicity and the known metabolic fate of these substances in man. Brief mention is made of specific analytical procedures that are applicable to the determination of each substance and its active metabolites in biological specimens. It is expected that such information will be of particular interest and use to toxicologists, pharmacologists, clinical chemists and clinicians who have need either to conduct an analytical search for these materials in specimens of human origin or to interpret 30 Amberwood Parkway analytical data resulting from such a search. Ashland, OH 44805 by Randall C. Baselt, Ph.D. Former Director, Chemical Toxicology Institute Bookmasters Foster City, California HARD BOUND, 7” x 10”, 2500 pp., 2017 ISBN 978-0-692-77499-1 USA Reviewer Comments on the Tenth Edition “...equally useful for clinical scientists and poison information centers and others engaged in practice and research involving drugs.” Y. Caplan, J. Anal. Tox. “...continues to be an invaluable and essential resource for the forensic toxicologist and pathologist.” D. Fuller, SOFT ToxTalk “...has become an essential reference book in many laboratories that deal with clinical or forensic cases of poisoning.” M.
    [Show full text]
  • Le Baclofène Et L'alcool 3 Nouveaux Paradigmes
    Académie Nationale de Pharmacie Lien d’intérêt : Ethypharm/Lundbeck 04/06/2014 Pr P.Jaury Université Paris Descartes 1 Les 3 nouveaux paradigmes proposés: l’abstinence totale ne serait plus nécessaire pour traiter les problèmes d’alcoolisme. « L’abstinence ,n’est plus un objectif mais une conséquence du traitement ». On pourrait soigner efficacement les patients non dépendants ayant un problème d’alcool. On pourrait obtenir « l’indifférence à l’alcool ». 04/06/2014 Pr P.Jaury Université Paris Descartes 2 LE BACLOFENE (AMM) Lioresal®: 1972. AMM : -contractures spastiques de la SEP. -contractures spastiques des affections médullaires (d'étiologie infectieuse, dégénérative, traumatique, néoplasique). -contractures spastiques d'origine cérébrale. -maximum 75 mg par jour en ambulatoire. 04/06/2014 Pr P.Jaury Université Paris Descartes 3 LE BACLOFENE et son action il augmente l’activité GABA (agoniste des récepteurs GABA b) et diminue celle du glutamate. Ce qui réduirait l’activité de la dopamine. Et donc action sur les mécanismes cérébraux de la récompense? 04/06/2014 Pr P.Jaury Université Paris Descartes 4 Médicaments et récepteurs GABA Les benzodiazépines, les barbituriques, le topiramate (Epitomax®), la gabapentine (Neurontin®), la prégabaline (Lyrica®) et les valproates (Dépamide®, Dépakine® et Dépakote®) agissent sur les récepteurs GABA a. Ainsi que l’acamprosate (Aotal ®). Les autres substances connues agissant sur les récepteurs GABA b sont le gamma- hydroxybutyrate ou GHB (Alcover® en Italie et en Autriche dans le traitement de l’alcoolisme en première intention) , le Phénibut® et le Picamilon® en Russie. 04/06/2014 5 Pr P.Jaury Université Paris Descartes LE BACLOFENE et la cocaïne À la dose de 5mg/kg, le baclofène réduit l’auto-administration de cocaïne chez le rat.
    [Show full text]
  • The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats
    W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 4-2017 The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats Justin P. Canakis College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Animal Sciences Commons, Exercise Science Commons, Laboratory and Basic Science Research Commons, and the Other Nutrition Commons Recommended Citation Canakis, Justin P., "The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats" (2017). Undergraduate Honors Theses. Paper 1128. https://scholarworks.wm.edu/honorstheses/1128 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. 1 2 Title Page……………………………………………………………………………………...…..1 Abstract…………………………………………………………………………………………....5 Acknowledgement……………………………………………………………………….………..6 Background.………………………………………………………………………..……………...7 DSEHA and its Effect on the VMS Industry………………...……………………………7 History of Adverse Side Effects from Pre-Workout Supplements ………….……………8 Ingredient Analysis ………………………………………..……………….……………..……....9 2.5g Beta-Alanine…………………………..……………………………………………..9 1g Creatine Nitrate……………………………...……………………………………..…12 500mg L-Leucine……………………………………………………………………...…16 500mg Agmatine Sulfate……………………….………………………………..………18
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.066,853 B2 Clay (45) Date of Patent: Jun
    USOO9066853B2 (12) United States Patent (10) Patent No.: US 9.066,853 B2 Clay (45) Date of Patent: Jun. 30, 2015 (54) CLONIDINE COMPOUNDS INA 3.? R 1939: Shashekar et al. BODEGRADABLE FIBER 6,723,741W - 4 B2 4/2004 Jeonawinney et al. 6,756,058 B2 6/2004 Brubaker et al. (71) Applicant: Warsaw Orthopedic, Inc., Warsaw, IN 6,773,714 B2 8, 2004 SN al (US) 6,921,541 B2 7/2005 Chasin et al. 6,974.462 B2 12/2005 Sater (72) Inventor: Danielle L. Clay, Collierville, TN (US) 7,166.5707,144,412 B2 12/20061/2007 Wolfetal.Hunter et al. 7,220.281 B2 5/2007 Lambrecht et al. (73) Assignee: Warsaw Orthopedic, Inc., Warsaw, IN 7,229,441 B2 6, 2007 E. t e (US) 7,235,043 B2 6/2007 Gellman et al. 7,287,983 B2 10/2007 Ilan (*) Notice: Subject to any disclaimer, the term of this 2. g E: 3. My patent is extended or adjusted under 35 7361, 168 B2 4/2008 Miiver et al. U.S.C. 154(b) by 0 days. 7,367,978 B2 5/2008 Drewry et al. 7,875,054 B2 * 1/2011 LaFontaine ................... 606,213 (21) Appl. No.: 13/741,475 8, 158,143 B2 * 4/2012 Lendlein et al. .............. 424/426 2002fOOO9454 A1 1/2002 Boone et al. 2002/0090398 A1 7/2002 Dunn et al. (22) Filed: Jan. 15, 2013 2002/0183855 A1 12/2002 Yamamoto et al. ........ 623/23.51 2003. O144570 A1* 7, 2003 Hunter et al. ...... (65) Prior Publication Data 2003/0153972 A1* 8, 2003 Helmus .......................
    [Show full text]
  • Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders
    Int. J. Biol. Sci. 2018, Vol. 14 341 Ivyspring International Publisher International Journal of Biological Sciences 2018; 14(3): 341-357. doi: 10.7150/ijbs.23247 Review Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders Ghulam Hussain1,3, Azhar Rasul4,5, Haseeb Anwar3, Nimra Aziz3, Aroona Razzaq3, Wei Wei1,2, Muhammad Ali4, Jiang Li2, Xiaomeng Li1 1. The Key Laboratory of Molecular Epigenetics of MOE, Institute of Genetics and Cytology, Northeast Normal University, Changchun 130024, China 2. Dental Hospital, Jilin University, Changchun 130021, China 3. Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000 Pakistan 4. Department of Zoology, Faculty of Life Sciences, Government College University, Faisalabad, 38000 Pakistan 5. Chemical Biology Research Group, RIKEN Center for Sustainable Resource Science. 2-1 Hirosawa, Wako, Saitama 351-0198 Japan Corresponding authors: Professor Xiaomeng Li, The Key Laboratory of Molecular Epigenetics of Ministry of Education, Institute of Genetics and Cytology, Northeast Normal University, 5268 People's Street, Changchun, Jilin 130024, P.R. China. E-mail: [email protected] Tel: +86 186 86531019; Fax: +86 431 85579335 or Professor Jiang Li, Department of Prosthodontics, Dental Hospital, Jilin University, 1500 Tsinghua Road, Changchun, Jilin 130021, P.R. China. E-mail: [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2017.10.09; Accepted: 2017.12.18; Published: 2018.03.09 Abstract Neurodegenerative diseases are conventionally demarcated as disorders with selective loss of neurons.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0290181 A1 Lee Et Al
    US 201502901 81A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0290181 A1 Lee et al. (43) Pub. Date: Oct. 15, 2015 (54) COMBINATION OF EFFECTIVE (52) U.S. Cl. SUBSTANCES CAUSING SYNERGISTIC CPC ............. A6 IK3I/445 (2013.01); A61 K3I/I66 EFFECTS OF MULTIPLE TARGETING AND (2013.01); A61 K3I/505 (2013.01); A61 K USE THEREOF 36/38 (2013.01); A61K 45/06 (2013.01); A61 K 36/744 (2013.01); A61K 36/69 (2013.01); (75) Inventors: Doo Hyun Lee, Seoul (KR); Sunyoung A61K 31/198 (2013.01); A61K 36/40 Cho, Gyeonggi-do (KR) (2013.01); A61 K36/884 (2013.01) (73) Assignee: VIVOZONE, INC., Seoul (KR) (57) ABSTRACT Disclosed are a combination of active components inducing (21) Appl. No.: 14/128,616 synergistic effects of multi-targeting and a use thereof. More particularly, disclosed are a functional food composition, a (22) PCT Filed: Jun. 28, 2012 cosmetic composition, a pain-suppressive composition, and a composition for treatment or prevention of pruritus or atopic (86). PCT No.: PCT/KR2O12/OOS145 dermatitis, which comprise as active components, two or S371 (c)(1), more components selected from a group consisting of (a) a (2), (4) Date: Jan. 16, 2014 5-hydroxytryptamine subtype 2 (5-HT2) receptor antagonist; (b) a P2X receptor antagonist; and (c) any one of a glycine (30) Foreign Application Priority Data receptor agonist, a glycine transporter (GlyT) antagonist, a gamma-aminobutyric acid (GABA) receptor agonist, and a Jun. 28, 2011 (KR) ........................ 10-2011-0063.289 GABA transporter 1 (GAT1) antagonist. The multi-targeting composite composition (specifically, natural Substances com Publication Classification posite composition) has synergistic effects, and thus a treat ment using a combination of respective components may (51) Int.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • Final- Test Database
    This document was exported from Numbers. Each table was converted to an Excel worksheet. All other objects on each Numbers sheet were placed on separate worksheets. Please be aware that formula calculations may differ in Excel. Numbers Sheet Name Numbers Table Name Excel Worksheet Name PARTTESTR1 Table 1 PARTTESTR1 LCMS methods Table 1 LCMS methods UPLC methods Table 1 UPLC methods Test Name Test Type TAT Detection Limit Min. Sample Amnt Method Reference Tags Aerobic Plate Count -- USP Aerobic Plate Count 5 Days <10 cfu/g 10 Grams USP <2021>/GL-411, APC, TAPC Purity Aerobic Plate Count -- FDA BAM Aerobic Plate Count 5 Days <10 cfu/g 10 Grams FDA BAM/GL-410, APC, TAPC Purity Aerobic Plate Count -- AOAC Aerobic Plate Count 5 Days <10 cfu/g 10 Grams AOAC 990.12/GL-412, APC, TAPC Purity Aerobic Plate Count -- EP Aerobic Plate Count 5 Days <10 cfu/g 10 Grams EP Purified Water/GL-391, APC, TAPC Purity Ash Ash 5 Days TBD 10 Grams USP <281>/GL-588 Identity Bacillus cereus Bacillus cereus 5 Days <10 cfu/g 10 Grams GL-483 Purity Bacillus coagulans Bacillus coagulans 5 Days <10 cfu/g 10 Grams GL-471 Purity Bacillus subtilis Bacillus subtilis 5 Days <10 cfu/g 10 Grams Customer Supplied Method Purity Bulk Density Bulk Density 5 Days TBD 10 Grams USP <616>/GL-587 Identity Calories Calories 5 Days TBD 10 Grams USDA Handbook No. 74, pp. 9-11 Potency Calories from Fat Calories 5 Days TBD 10 Grams 21 CFR Part 101.9 (Calc.) Potency Calories from Saturated Fat Calories 5 Days TBD 10 Grams 21 CFR Part 101.9 (Calc.) Potency Carbohydrates Carbohydrates 5 Days TBD 10 Grams Calculation Potency Coliforms -- FDA BAM Coliforms 5 Days <10 cfu/g 10 Grams FDA BAM/GL-422 Purity Coliforms -- AOAC Coliforms 5 Days <10 cfu/g 10 Grams AOAC 991.14/GL-420 Purity Coliforms -- CMMEF Coliforms 5 Days <10 cfu/g 10 Grams CMMEF/GL-391 Purity Density of Solids Density 5 Days TBD 10 Grams USP <699> Identity Mercury (Hg) DMA 5 Days TBD 10 Grams EPA 7473/GL-585 Purity E.
    [Show full text]
  • WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 15/00 (2006.01) A24F 47/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/072426 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 27 November 2013 (27.1 1.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/730,738 28 November 2012 (28. 11.2012) US 61/794,601 15 March 2013 (15.03.2013) US (84) Designated States (unless otherwise indicated, for every 61/83 1,992 6 June 2013 (06.06.2013) us kind of regional protection available): ARIPO (BW, GH, 61/887,045 4 October 201 3 (04.
    [Show full text]